Key result
Tirzepatide cuts HALT ~61% and reduces paravalvular leak at 6 months in obese TAVR patients.
Why the study?
Obesity predisposes to subclinical leaflet thrombosis, hypo-attenuated leaflet thickening, and paravalvular leak after TAVR, but the impact of tirzepatide on post-TAVR valve performance had not been evaluated.
Does tirzepatide therapy reduce the incidence of HALT and PVL in obese patients undergoing TAVR?
RCT (n=260)
Open-label
Randomized
Yes
Does tirzepatide therapy reduce the incidence of HALT and PVL in obese patients undergoing TAVR?
Tirzepatide therapy significantly improves post-TAVR valve healing and hemodynamics by reducing subclinical leaflet thrombosis and paravalvular leak in obese patients.
Answers are grounded in this paper and cite their sources.
Supports tirzepatide around TAVR in obese patients; provides first RCT evidence for this strategy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Thirugnanam et al. (2026) conducted an RCT in Obesity in patients undergoing TAVR (n=260). Tirzepatide was evaluated on Incidence of hypo-attenuated leaflet thickening (HALT) (p=0.002). Tirzepatide therapy reduced the incidence of HALT and ≥ mild paravalvular leak at 6 months in obese patients undergoing TAVR.
Synapse has enriched 10 related papers. Consider them for comparative context: